As an incomparable leader in the in vitro diagnostics (IVD) antibodies market, Creative Biolabs provides a full range of IVD antibodies custom development service against chromosome 9p21marker for the diagnosis of bladder cancer. With our advanced technology and experienced scientists in antibody manufacture, we are confident in providing high-quality services to accelerate your programs.

Introduction of Chromosome 9p21

Chromosome 9 is the most frequent genetic lesion in bladder carcinogenesis. As one of the tumor suppressor genes loci found on chromosome 9, 9p21 is involved in numerous cell cycle regulation and cellular senescence. Importantly, germline variants in the 9p21 region have been associated with the risk of several cancers. In addition, somatic mutations and deletions of the 9p21 region have been observed in a variety of tumors, underscoring an important role of this genomic region in cancer etiology. This region harbors a cluster of interferon (IFN) genes, several tumor suppressor genes, including cyclin-dependent kinase inhibitors 2A (CDKN2A), CDKN2B, CDKN2B-AS1 and MTAP and other genes with a less well-established role in cancer, including ELAVL2, TUSC1, MOB3B, C9orf72, LINGO2, and ACO1.

Loss of heterozygosity (LOH) at 9p21 in bladder cancers.Fig.1 Loss of heterozygosity (LOH) at 9p21 in bladder cancers. (Florl A R., 2000)

Chromosome 9p21 Marker of Bladder Cancer

Alteration of chromosome 9 is a common denominator in human neoplasia which is associated with the growth promotion and clonal expansion of various tumors including carcinoma of the bladder. Also, chromosome 9p21 locus is frequently deleted in the early stages of bladder cancer, as the putative tumor suppressor genes (MTS 1 and 2) were mapped to this region. Moreover, the MTS genes may represent ultimate targets of deletions in the 9p21region and other distinct loci on chromosome 9 that could be altered in pathogenetic subsets of human tumors. Studies have suggested that the 9p21aberrations are associated with the recurrence of urothelial carcinoma of the urinary bladder which enables it a potential biomarker for the initial diagnostics of bladder cancer.

IVD Antibodies for Chromosome 9p21 Marker

Based on years of experience in IVD antibody development, Creative Biolabs has developed a series of high-quality services for our worldwide customers to promote the development of their programs. Currently, IVD antibodies are widely used as diagnostic tools all over the world for the analysis of numerous biomolecules. With the rapid development of IVD technology, IVD antibodies are exploited for the diagnosis of a variety of diseases which include but not limited to bladder cancer.

We are happy to offer various high-affinity IVD antibody development services for chromosome 9p21 marker to meet every customer's requirements. For more detailed information, please feel free to contact us and get a quote.

Reference

  1. Florl A R, et al. (2000). “DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder.” Laboratory investigation, 80(10): 1513.

For Research Use Only.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2024 Creative Biolabs.
Inquiry Basket